Neumora Therapeutics is trading 10.4% up at $1.65 as the broader biotech sector rallies on blockbuster M&A activity and positive trial data across the space.
- The move is driven by improved sentiment toward the biotech industry, with the XBI ETF gaining approximately 2.3%.
- Shares are seeing follow-through momentum after recently reported favorable toxicology results for NMRA-215, which support plans for an IND submission in late 2026.
- There is no fresh, company-specific news today; the double-digit gain appears to be a result of sector-wide strength and recent clinical progress.